SMMT vs. BHVN, RARE, IDYA, XENE, PBH, AXSM, CORT, HCM, ARWR, and INSM
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), and Insmed (INSM). These companies are all part of the "pharmaceutical preparations" industry.
Summit Therapeutics (NASDAQ:SMMT) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 83.7% of Summit Therapeutics shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Biohaven had 27 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for Biohaven and 0 mentions for Summit Therapeutics. Biohaven's average media sentiment score of 0.44 beat Summit Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.
Summit Therapeutics has a beta of -1.13, suggesting that its share price is 213% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Biohaven has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics' return on equity of -125.07% beat Biohaven's return on equity.
Summit Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 68.92%. Biohaven has a consensus target price of $51.63, suggesting a potential upside of 38.15%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Biohaven.
Biohaven received 86 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 65.43% of users gave Biohaven an outperform vote while only 57.00% of users gave Summit Therapeutics an outperform vote.
Summary
Biohaven beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
